Accessible and affordable tests to advance early detection of heritable cancers in European regions
The HORIZON-MISS-2024-CANCER-01-03 funding program aims to improve the lives of people in European regions by advancing the early detection of heritable cancers through accessible and affordable tests. This initiative focuses on validating, piloting, and upscaling innovative diagnostic solutions, contributing to the broader EU Mission on Cancer objectives of prevention, optimized diagnostics, and equitable access to healthcare.
Who is Funded
This section outlines the types of entities and geographical areas eligible for funding under the program, alongside the primary goals it seeks to achieve. The program primarily targets consortia comprising various organizations, focusing on improving cancer detection across European Union Member States and Associated Countries, with a special emphasis on specific Eastern and Southern European regions. Its core objective is to advance early and equitable cancer detection and treatment.
What is Funded
This section details the types of projects, thematic areas, and activities eligible for funding, focusing on innovative diagnostics and healthcare solutions. It outlines the specific industries and research fields supported, clarifies the covered costs by referring to general guidelines, and specifies the maturity levels of projects that are targeted for support.
Type and Scope of Funding
This section details the financial aspects of the funding program, including the type of support provided and the maximum amounts available per project. The program offers financial support in the form of grants, with a substantial total budget allocated to advance the early detection of heritable cancers across Europe.
Conditions and Requirements
This section outlines the essential rules, regulations, and specific conditions that applicants and beneficiaries must adhere to. It details critical stipulations for application and post-award, emphasizes the mandatory consortium structure, specifies budget limitations, and highlights other important regulatory and operational requirements to ensure the effective implementation of projects.
Application Procedure
This section outlines the process for submitting applications and the methods used for evaluating proposals and communicating decisions. The application period for this call has concluded, with proposals undergoing a single-stage submission and a rigorous evaluation process that prioritizes impact and specific cancer research areas.
Legal Basis
This section identifies the foundational legal and official documents that establish and govern the funding program. It specifies the core authorization framework and lists other significant regulations and policies that shape its implementation, providing clarity on the program's legal underpinnings and where official texts can be accessed.
Similar Programs
Funding Overview
Funding Status:
Closed
Maximum Amount:
12,000,000 €
Allocated Budget:
35,000,000.00 €
Award Channel:
Competitive Tender
Region:
European Union (Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden), Associated Countries; projects must be extensively piloted and upscaled in at least three regions across at least three different Member States or Associated Countries, with one region specifically from Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Portugal, Romania, Slovakia, or Slovenia.
Sectors:
Healthcare, Medical Technology, Research and Development, Information and Communication Technology, Other
Beneficiaries:
People and their families at heritable genetic risk of developing cancer, civil society, foundations, innovators, regional and national policymakers and authorities.
Application Type:
Consortium Required
Funding Stages:
Applied Research, Experimental Development, Pilot Testing, Market Introduction, Other
Funding Provider
Program Level:
European Union
Funding Body:
European Commission
Managed By:
European Commission
Additional Partners:
EIT-Health KIC networks (encouraged collaboration), Knowledge Centre on Cancer (KCC) (for result uptake), Regional Health and Care Agencies, European Regional and Local Health Authorities (EUREGHA).
Website: